united healthcare preventive care services :: Article CreatorMedical And Prescription Plan Information - Medical Care And Pharmacy Benefits
When on campus, PUSH should be the initial contact unless it is of an emergency nature (life-threatening). When seen by a PUSH provider, your deductible is waived.
There will be a $15 co-pay for some PUSH services such as x-rays, physical therapy, and other ancillary services. Laboratory services constitute a 10% co-insurance of services rendered.
A $200 deductible for in-network preferred providers and a $400 deductible for out-of-network providers will apply to all services outside PUSH.
Preventive care services are only covered if performed by an United Healthcare in-network provider.
LabCorp, located in PUSH is in the United Healthcare network, and all preferred network coverage will apply.
The Purdue University Pharmacy (PUP) is the preferred pharmacy of the plan. Insured students and their insured dependents can have prescriptions filled at the pharmacy located in RHPH building, Room 118. A $10 copay for Tier 1 drugs, $20 copay for Tier 2 and Tier 3 drugs and a $50 copay for Tier 4 drugs applies to each covered prescription at PUP.
Please note: when you do not use PUP, prescriptions can only be filled at an United Healthcare network pharmacy, co-pay rates are higher outside of PUP.
Most US Providers will file claims to United Healthcare for services received. All claims must be submitted to insurance within 90 days of the date of service.
For in-network care across the United States choose:
United Healthcare Choice Plus Network Find a Provider link: http://www.Uhcsr.Com/lookupredirect.Aspx?Delsys=52
Best Short-Term Health Insurance Providers
Short-term health or short-term medical insurance plans can fill a temporary gap in health insurance coverage. They can be a good fit for people who can't get group health insurance or COBRA, or who can't enroll in better coverage through an Affordable Care Act (ACA) plan because they missed open enrollment and aren't eligible for special enrollment. The best short-term health insurance plans cover essential benefits at an affordable price. It's important to understand that short-term health insurance isn't an adequate replacement for traditional major medical coverage. The plans are not required to cover the same essential health benefits required of ACA plans, deductibles are often very high, and pre-existing conditions are typically not covered. For these reasons, short-term health coverage has been called "junk insurance" and is only available in around 38 states. The Biden administration issued a rule on March 28, 2024, limiting short-term health insurance plans to three months, with a single one-month extension allowed. The aim is to protect consumers from relying on them for more than a few months, and instead steer them toward more comprehensive insurance plans. The rule applies to policies issued on Sept. 1, 2024, or later. For now, though, the plans have fewer restrictions. And despite their drawbacks, there may be times when you need to use a short-term plan in a pinch. We researched 17 plans from three major health insurance companies and evaluated their maximum coverage benefits, length of coverage, costs, prescription drug coverage, and state availability.
UnitedHealthcare Has Changed Course Regarding Its Controversial Prior Authorization Policy For Surveillance And Diagnostic Colonoscopies [Update]
UnitedHealthcare implements controversial prior authorization policy for surveillance and diagnostic ... [+] colonoscopies.
getty
In late May, UnitedHealthcare, the nation's largest health insurer by membership, announced it would implement a prior authorization policy for surveillance and diagnostic colonoscopies. The coverage policy entailed that any UnitedHealthcare enrollee seeking surveillance and diagnostic colonoscopies to detect cancer would first require pre-approval from the insurer.
But, perhaps in response to a public outcry, UnitedHealthcare has softened its prior authorization policy somewhat. In its revised form posted last week, the policy calls for "advance notification," which requires physicians to let the insurer know they'll be performing certain gastrointestinal procedures, including surveillance and diagnostic colonoscopies, and provide information such as why these are needed. UnitedHealthcare says the new policy will not lead to denials of care if it's clinically indicated.
Notably, the policy - both in its original and present form - does not apply to screening colonoscopy, which is the routine procedure generally conducted once every ten years to examine the large intestine for ulcers, polyps, and cancer in low-risk members of the general population between the ages of 45 and 74.
What makes the new policy regarding surveillance and diagnostic colonoscopy particularly controversial is that it goes against the grain of what many experts in the field - gastroenterologists, but also health economists - would consider a rational pathway. Erecting barriers to access for those who are at risk and therefore more likely to develop colorectal cancer doesn't make sense.
Specifically, surveillance colonoscopy is indicated for individuals who have a personal history of cancer or colorectal polyps, or conditions that predispose them to colorectal cancer. And, diagnostic colonoscopy is used for individuals with symptoms of cancer, or for those who've either had a positive stool test or had polyps detected on routine screening colonoscopies.
UnitedHealthcare has stated that prior authorizations can be completed relatively quickly, within two days. In addition, in an emailed statement to STAT, a UnitedHealthcare representative defended the policy as follows: "Multiple clinical studies have shown significant overutilization or unnecessary use of non-screening gastroenterology endoscopy procedures which may expose our members to unnecessary medical risks and additional out of pocket costs."
Overuse of non-screening endoscopic procedures (in both the upper and lower digestive tract) can indeed lead to risk and safety issues for patients. Additionally, there are questions surrounding the cost-effectiveness of screening asymptomatic, low-risk individuals for certain cancers.
However, there is considerably less doubt that at-risk individuals for colorectal cancer should be tested and that it's cost-effective to do so. Indeed, surveillance and diagnostic colonoscopies for high-risk individuals have been part and parcel of clinical practice guidelines for quite some time. Moreover, surveillance colonoscopy is cost-effective for patients who are at high risk for developing colorectal cancer.
Notably, prior to this year, Medicare had a somewhat analogous coverage policy, which was heavily criticized and subsequently reversed. Previously, Medicare would pay for, say, a Cologuard test, used to periodically screen adults 45 years of age and older who are at average risk for colorectal cancer by detecting certain DNA markers and blood in the stool. But if the test result was positive Medicare wouldn't necessarily pay for a follow-up colonoscopy.
Recently enacted policy changes require Medicare and most commercial insurers to pay for colonoscopy after a positive Cologuard test without out-of-pocket costs to the patient. This change took effect starting January 1, 2023. The update to expand Medicare coverage policies for colorectal cancer screening explicitly aligns with recent United States Preventive Services Task Force and professional medical society recommendations. This includes expanding Medicare coverage for certain colorectal cancer screening tests by reducing the minimum age payment and coverage limitation from 50 to 45 years. Second, it expands the regulatory definition of colorectal cancer screening tests to include what is deemed "complete colorectal cancer screening," in which a follow-up colonoscopy after a Medicare-covered stool-based colorectal cancer diagnostic test returns a positive result.
Prior authorization and advance notification
UnitedHealthcare's new protocol - whether in the form of prior authorization or advance notification - won't eliminate reimbursement of surveillance and diagnostic colonoscopies. Prior authorization and advance notification aren't the same thing as exclusion from coverage.
If used judiciously, such policies are intended to be checks on overutilization of technologies and services in the healthcare system. Insurers such as UnitedHealthcare say that by requiring physicians to demonstrate that an intervention is medically necessary before they agree to cover it, they can prevent overuse of technologies and medical services that patients may not actually need. Alternatively, insurers can nudge doctors towards the use of other less costly alternatives.
But this presumes the alternatives work as well or better than the intervention placed under prior authorization protocol. And in the case of surveillance and diagnostic colonoscopies for at-risk individuals that presumption is far from self-evident. Moreover, prior authorization tends to be a fairly blunt instrument that doesn't work well as a cost containment measure. To illustrate, upon appeal, of 35 million prior authorization requests to Medicare Advantage Plans in 2021 82% were overturned.
In the end, prior authorization or advance notification, in instances like the one in question in this article, isn't conducive to better practice of medicine or a more cost-effective way of doing colorectal cancer testing. In fact, by creating more paperwork and confusion, it's likely to cause a backlash in which healthcare providers and patients are strongly dissatisfied. In turn, this could lead to a reversal in policy, just as we saw with Medicare.
Comments
Post a Comment